About Amerise Biosciences Limited
Data last updated: 18 February 2026
Amerise Biosciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 27 August 1984, the company has been in operation for over 42 years.
Registered with ROC Ahmedabad under CIN L29199GJ1984PLC007195. Listed on BSE: 531681.
Capital: an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹6.61 Cr. Formerly known as Amradeep Industries Limited. It is led by directors including Manisha Maneklal Patel and Albert Hines.
Last AGM: 23 September 2025. Financial statements filed for year ended 31 March 2025. Office: 24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014.
As per the financials filed for FY 2025, the company reported a revenue of ₹18.8 Lakh, reflecting significant growth compared to the previous year.
As per MCA filings, the company has open charges of ₹38.39 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website amradeepindustries.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Amerise Biosciences Limited
Amerise Biosciences Limited has one previous CIN (Corporate Identification Number): U29199GJ1984PLC007195. The current CIN is L29199GJ1984PLC007195, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L29199GJ1984PLC007195 | Current |
| U29199GJ1984PLC007195 | Previous |
Auditor Details of Amerise Biosciences Limited
Amerise Biosciences Limited is audited by Bipin & Co Chartered Accountants (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Bipin & Co Chartered Accountants (ICAI peer reviewed, certificate valid till 2028-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Amerise Biosciences Limited
Amerise Biosciences Limited is currently managed by 4 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Manisha Maneklal Patel
Also directs:
Amraworld Agrico Limited, Presha Metallurgical Limited, Amerise Biosciences Limited and 2 more
|
Director | 24 Jun 2019 | 7 Years 0 Months | Current |
| Albert Hines | Whole-Time Director | 02 Feb 2026 | 0 Years 5 Months | Current |
| Kelash Bunkar | Director | 03 Feb 2025 | 1 Years 5 Months | Current |
Financials of Amerise Biosciences Limited FY 2026 filings available
Amerise Biosciences Limited reported revenue of ₹25.52 Lakh (up 35.74% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹25.52 Lakh | ₹18.8 Lakh | ₹0 | ₹0 | ₹9.58 Cr | ₹0 | ₹0 | ₹1.18 Cr |
| Other Income | ₹0 | ₹0 | ₹3.59 Lakh | ₹87,000 | ₹0 | -₹16.9 Lakh | ₹6,000 | ₹0 |
| Total Income | ₹25.52 Lakh | ₹18.8 Lakh | ₹3.59 Lakh | ₹87,000 | ₹9.58 Cr | -₹16.9 Lakh | ₹6,000 | ₹1.18 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹8.91 Cr | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹1.16 Cr |
| Employee Benefit Expense | ₹7.37 Lakh | ₹10.18 Lakh | ₹6.97 Lakh | ₹1.95 Lakh | ₹5.31 Lakh | ₹4.27 Lakh | ₹3.75 Lakh | ₹80,000 |
| Finance Costs | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹3,000 | ₹0 |
| Depreciation & Amortisation | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Expenses | ₹16.09 Lakh | ₹7.86 Lakh | ₹11.23 Lakh | ₹10.81 Lakh | ₹6.05 Lakh | ₹12.54 Lakh | ₹11.19 Lakh | ₹59,000 |
| Total Expenses | ₹23.46 Lakh | ₹18.04 Lakh | ₹18.2 Lakh | ₹12.76 Lakh | ₹9.03 Cr | ₹16.81 Lakh | ₹14.97 Lakh | ₹1.18 Cr |
| Profit Before Exceptional Items & Tax | ₹2.06 Lakh | ₹76,000 | -₹14.61 Lakh | -₹11.89 Lakh | ₹54.92 Lakh | -₹33.71 Lakh | -₹14.91 Lakh | ₹41,000 |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹2.06 Lakh | ₹76,000 | -₹14.61 Lakh | -₹11.89 Lakh | ₹54.92 Lakh | -₹33.71 Lakh | -₹14.91 Lakh | ₹41,000 |
| Total Tax Expense | ₹45,000 | ₹19,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹1.61 Lakh | ₹57,000 | -₹14.61 Lakh | -₹11.89 Lakh | ₹54.92 Lakh | -₹33.71 Lakh | -₹14.91 Lakh | ₹41,000 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.61 Lakh | ₹57,000 | -₹14.61 Lakh | -₹11.89 Lakh | ₹54.92 Lakh | -₹33.71 Lakh | -₹14.91 Lakh | ₹41,000 |
| EBITDA (computed) | ₹2.06 Lakh | ₹76,000 | -₹14.61 Lakh | -₹11.89 Lakh | ₹54.92 Lakh | -₹33.71 Lakh | -₹14.88 Lakh | ₹41,000 |
| Basic EPS | ₹0.00 | ₹0.00 | ₹-0.02 | ₹-0.02 | ₹0.08 | ₹-0.05 | ₹-0.02 | ₹0.00 |
| Diluted EPS | ₹0.00 | ₹0.00 | ₹-0.02 | ₹-0.02 | ₹0.08 | ₹-0.05 | ₹-0.02 | ₹0.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹7.42 Cr | ₹8.46 Cr | ₹5.39 Cr | ₹5.65 Cr | ₹11.99 Cr | ₹5.63 Cr | ₹6.02 Cr | ₹5.6 Cr |
| Non-current Assets | ₹6.81 Cr | ₹8.44 Cr | ₹5.37 Cr | ₹5.63 Cr | ₹5.76 Cr | ₹5.61 Cr | ₹6 Cr | ₹2.26 Cr |
| Current Assets | ₹61.19 Lakh | ₹2.69 Lakh | ₹2.29 Lakh | ₹1.36 Lakh | ₹6.23 Cr | ₹1.93 Lakh | ₹2.52 Lakh | ₹3.34 Cr |
| Property, Plant & Equipment | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹0 | ₹0 | ₹0 | ₹0 | ₹6.22 Cr | ₹0 | ₹0 | ₹3.32 Cr |
| Cash & Equivalents | ₹1.77 Lakh | ₹1.14 Lakh | ₹1.19 Lakh | ₹1.29 Lakh | ₹1.2 Lakh | ₹1.92 Lakh | ₹2.48 Lakh | ₹1.84 Lakh |
| Equity (Net Worth) | ₹5.4 Cr | ₹5.38 Cr | ₹5.37 Cr | ₹5.52 Cr | ₹5.64 Cr | ₹5.09 Cr | ₹5.43 Cr | ₹5.58 Cr |
| Equity Share Capital | ₹6.61 Cr | ₹6.61 Cr | ₹6.61 Cr | ₹6.61 Cr | ₹6.61 Cr | ₹6.61 Cr | ₹6.61 Cr | ₹6.61 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹9 Lakh | ₹8.26 Lakh | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹9 Lakh | ₹8.26 Lakh | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹2.03 Cr | ₹3.08 Cr | ₹1.55 Lakh | ₹3.69 Lakh | ₹6.27 Cr | ₹53.78 Lakh | ₹59.52 Lakh | ₹2.48 Lakh |
| Total Liabilities | ₹2.03 Cr | ₹3.08 Cr | ₹1.55 Lakh | ₹12.69 Lakh | ₹6.35 Cr | ₹53.78 Lakh | ₹59.52 Lakh | ₹2.48 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹1.06 Cr | ₹3.07 Cr | -₹16.94 Lakh | -₹13.21 Lakh | ₹6.15 Lakh |
| Investing Cash Flow | ₹1.63 Cr | -₹3.07 Cr | ₹26.69 Lakh | ₹12.54 Lakh | -₹15.05 Lakh |
| Financing Cash Flow | ₹0 | ₹0 | -₹9 Lakh | ₹74,000 | ₹8.26 Lakh |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹1.06 Cr | ₹3.07 Cr | -₹16.94 Lakh | -₹13.21 Lakh | ₹6.15 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹56.97 Lakh | ₹11,000 | ₹75,000 | ₹7,000 | -₹64,000 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7.92 Lakh | ₹0 | ₹0 | ₹6.37 Lakh | ₹18.8 Lakh | ₹0 | ₹0 | ₹0 |
| Other Income | ₹0 | ₹4.49 Lakh | ₹6.75 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Income | ₹7.92 Lakh | ₹4.49 Lakh | ₹6.75 Lakh | ₹6.37 Lakh | ₹18.8 Lakh | ₹0 | ₹0 | ₹0 |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹1.45 Lakh | ₹1.8 Lakh | ₹1.8 Lakh | ₹2.32 Lakh | ₹7.98 Lakh | ₹97,000 | ₹64,000 | ₹60,000 |
| Finance Costs | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Expenses | ₹34,000 | ₹1.72 Lakh | ₹9.18 Lakh | ₹4.86 Lakh | ₹23,000 | ₹63,000 | ₹2.73 Lakh | ₹4.27 Lakh |
| Total Expenses | ₹1.79 Lakh | ₹3.52 Lakh | ₹10.98 Lakh | ₹7.18 Lakh | ₹8.21 Lakh | ₹1.6 Lakh | ₹3.37 Lakh | ₹4.87 Lakh |
| Profit Before Exceptional Items & Tax | ₹6.13 Lakh | ₹97,000 | -₹4.23 Lakh | -₹81,000 | ₹10.59 Lakh | -₹1.6 Lakh | -₹3.37 Lakh | -₹4.87 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹6.13 Lakh | ₹97,000 | -₹4.23 Lakh | -₹81,000 | ₹10.59 Lakh | -₹1.6 Lakh | -₹3.37 Lakh | -₹4.87 Lakh |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹6.13 Lakh | ₹97,000 | -₹4.23 Lakh | -₹81,000 | ₹10.59 Lakh | -₹1.6 Lakh | -₹3.37 Lakh | -₹4.87 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹6.13 Lakh | ₹97,000 | -₹4.23 Lakh | -₹81,000 | ₹10.59 Lakh | -₹1.6 Lakh | -₹3.37 Lakh | -₹4.87 Lakh |
| EBITDA (computed) | ₹6.13 Lakh | ₹97,000 | -₹4.23 Lakh | -₹81,000 | ₹10.59 Lakh | -₹1.6 Lakh | -₹3.37 Lakh | -₹4.87 Lakh |
| Basic EPS | ₹0.01 | ₹0.00 | ₹-0.01 | ₹0.00 | ₹0.02 | ₹0.00 | ₹-0.01 | ₹-0.01 |
| Diluted EPS | ₹0.01 | ₹0.00 | ₹-0.01 | ₹0.00 | ₹0.02 | ₹0.00 | ₹-0.01 | ₹-0.01 |
Shareholding Pattern of Amerise Biosciences Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, retail and other public shareholders hold 100.00% of Amerise Biosciences Limited. The company had 34,519 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | - | - | - | - | - | - |
| Public | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | - | - | - |
| Public | 100.00% | 100.00% | 100.00% |
| Promoter change (YoY, %pts) | - | - | - |
Charges & Borrowings of Amerise Biosciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Mar 1987 | Bank of Baroda | ₹9 Lakh | Open |
| 20 Aug 1985 | Gujarat State Financial Corporation | ₹29.39 Lakh | Open |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Amerise Biosciences Limited
View historical data on people associated with Amerise Biosciences Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Amerise Biosciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Amerise Biosciences Limited
GSTIN & GST Filing Data of Amerise Biosciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Amerise Biosciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Amerise Biosciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Amerise Biosciences Limited
MSME Payment Delays by Amerise Biosciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Amerise Biosciences Limited
Subsidiaries & Group Companies of Amerise Biosciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Amerise Biosciences Limited with ownership details.
MCA Filings & Documents of Amerise Biosciences Limited
MCA Filings & Documents of Amerise Biosciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Amerise Biosciences Limited
Frequently Asked Questions about Amerise Biosciences Limited
Amerise Biosciences Limited is an active public limited company in the pharma sector based in Ahmedabad, Gujarat, India. It was incorporated on 27 August 1984 (42+ years old) and is registered under CIN L29199GJ1984PLC007195. Listed on BSE: 531681.
Amerise Biosciences Limited reported revenue of ₹18.8 Lakh for FY 2025 (up 424.00% YoY).
The current directors of Amerise Biosciences Limited are:
- Manisha Maneklal Patel
- Minal Vinodkumar Lakhlani
- Albert Hines
- Kelash Bunkar
The primary industry of Amerise Biosciences Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Amerise Biosciences Limited is listed on BSE with code 531681.
Amerise Biosciences Limited can be reached at the registered office: 24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014, or through the website amradeepindustries.in.